News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,367 Results
Type
Article (41379)
Company Profile (263)
Press Release (689710)
Multimedia
Podcasts (92)
Webinars (20)
Section
Business (204852)
Career Advice (2032)
Deals (35586)
Drug Delivery (130)
Drug Development (81533)
Employer Resources (173)
FDA (16513)
Job Trends (14984)
News (346853)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2597)
Accelerated approval (49)
Adcomms (27)
Allergies (171)
Alliances (49579)
ALS (212)
Alzheimer's disease (1801)
Antibody-drug conjugate (ADC) (462)
Approvals (16917)
Artificial intelligence (671)
Autoimmune disease (297)
Automation (56)
Bankruptcy (362)
Best Places to Work (11635)
BIOSECURE Act (20)
Biosimilars (223)
Biotechnology (170)
Bladder cancer (198)
Brain cancer (72)
Breast cancer (761)
Cancer (5886)
Cardiovascular disease (476)
Career advice (1726)
Career pathing (43)
CAR-T (333)
CDC (56)
Celiac Disease (3)
Cell therapy (907)
Cervical cancer (47)
Clinical research (70919)
Collaboration (2071)
Company closure (5)
Compensation (1412)
Complete response letters (80)
COVID-19 (2743)
CRISPR (108)
C-suite (1139)
Cystic fibrosis (152)
Data (8014)
Decentralized trials (3)
Denatured (28)
Depression (161)
Dermatology (89)
Diabetes (588)
Diagnostics (6939)
Digital health (55)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (323)
Drug pricing (201)
Drug shortages (31)
Duchenne muscular dystrophy (285)
Earnings (92137)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119689)
Executive appointments (1084)
FDA (20275)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1735)
Gene editing (234)
Generative AI (56)
Gene therapy (724)
GLP-1 (1057)
Government (4732)
Grass and pollen (6)
Guidances (408)
Healthcare (19018)
HIV (80)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (289)
Immuno-oncology (93)
Indications (196)
Infectious disease (3086)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (292)
Interviews (319)
IPO (16668)
IRA (50)
Job creations (3647)
Job search strategy (1431)
JPM (58)
Kidney cancer (19)
Labor market (102)
Layoffs (564)
Leadership (40)
Legal (7953)
Liver cancer (100)
Longevity (32)
Lung cancer (775)
Lymphoma (432)
Machine learning (60)
Management (59)
Manufacturing (1059)
MASH (190)
Medical device (13942)
Medtech (14070)
Mergers & acquisitions (20177)
Metabolic disorders (1510)
mRNA (210)
Multiple sclerosis (189)
NASH (17)
Neurodegenerative disease (421)
Neuropsychiatric disorders (105)
Neuroscience (3321)
Neurotech (1)
NextGen: Class of 2026 (6520)
Non-profit (4531)
Now hiring (78)
Obesity (707)
Opinion (288)
Ovarian cancer (226)
Pain (258)
Pancreatic cancer (309)
Parkinson's disease (364)
Partnered (33)
Patents (599)
Patient recruitment (676)
Peanut (62)
People (59623)
Pharmaceutical (58)
Pharmacy benefit managers (32)
Phase 1 (22105)
Phase 2 (31251)
Phase 3 (23243)
Pipeline (8914)
Policy (319)
Postmarket research (2569)
Preclinical (9423)
Press Release (64)
Prostate cancer (308)
Psychedelics (54)
Radiopharmaceuticals (326)
Rare diseases (1085)
Real estate (5972)
Recruiting (70)
Regulatory (25451)
Reports (56)
Research institute (2413)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (22)
RSV (88)
Schizophrenia (178)
Series A (289)
Series B (214)
Service/supplier (11)
Sickle cell disease (112)
Special edition (24)
Spinal muscular atrophy (166)
Sponsored (48)
Startups (3641)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (62)
Vaccines (1098)
Venture capital (110)
Weight loss (454)
Women's health (128)
Worklife (20)
Date
Today (42)
Last 7 days (655)
Last 30 days (3279)
Last 365 days (30071)
2026 (13120)
2025 (30171)
2024 (35208)
2023 (40072)
2022 (51174)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (93)
Alaska (7)
Arizona (350)
Arkansas (14)
Asia (39707)
Australia (6512)
California (13402)
Canada (3799)
China (1360)
Colorado (569)
Connecticut (579)
Delaware (413)
Europe (85943)
Florida (2008)
Georgia (430)
Hawaii (3)
Idaho (62)
Illinois (1059)
India (90)
Indiana (604)
Iowa (23)
Japan (542)
Kansas (131)
Kentucky (50)
Louisiana (42)
Maine (76)
Maryland (1601)
Massachusetts (9551)
Michigan (366)
Minnesota (726)
Mississippi (6)
Missouri (145)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3515)
New Mexico (29)
New York (3497)
North Carolina (1695)
North Dakota (9)
Northern California (6732)
Ohio (399)
Oklahoma (23)
Oregon (41)
Pennsylvania (2692)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (86)
South Dakota (2)
Southern California (5289)
Tennessee (214)
Texas (2132)
United States (47212)
Utah (398)
Vermont (1)
Virginia (323)
Washington D.C. (80)
Washington State (1066)
West Virginia (4)
Wisconsin (127)
Wyoming (2)
731,367 Results for "rezolute inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug
While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral factors. The FDA acknowledged the validity of this argument.
March 24, 2026
·
3 min read
·
Heather McKenzie
Press Releases
Rezolute to Participate in Upcoming Investor Conferences - May 11, 2026
May 11, 2026
·
1 min read
Press Releases
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 13, 2026
·
7 min read
Press Releases
Rezolute to Participate in the Citizens Life Sciences Conference
March 4, 2026
·
1 min read
Press Releases
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
March 24, 2026
·
7 min read
Press Releases
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
·
1 min read
Press Releases
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
April 21, 2026
·
4 min read
Press Releases
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 3, 2026
·
9 min read
Press Releases
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
February 12, 2026
·
7 min read
Press Releases
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
December 11, 2025
·
6 min read
1 of 73,137
Next
